secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001213900-23-038128
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial receives $450K upfront, 19.9% stake in Adovate, and up to $83M milestones for Purnovate sale
--------------------------------------------------------------------------------

- Adovate exercised irrevocable option to acquire Purnovate assets effective May 16, 2023.
- Adial received $450,000 non-refundable fee and will be reimbursed ~$0.9M for prior Purnovate expenses.
- Eligible for up to $33M development/approval milestones (first three compounds) plus $50M commercial milestones.
- Adial receives 19.9% equity in Adovate and ongoing low single-digit royalties on net sales.
- William Stilley (former CEO) departs active management; will remain on Adial board and lead Adovate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023038128/0001213900-23-038128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023038128/ea178264-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-038128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer